Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Induced Pluripotent Stem Cells Market

ID: MRFR/MED/51002-HCR
128 Pages
Nidhi Mandole
Last Updated: February 06, 2026

US Induced Pluripotent Stem Cells Market Research Report: Size, Share, Trend Analysis By Applications (Regenerative Medicine, Drug Discovery, Disease Modeling, Toxicology Testing, Gene Therapy), By Cell Type (Cardiomyocytes, Neurons, Hepatocytes, Pancreatic Cells, Mesenchymal Stem Cells), By Source of Induction (Transcription Factors, Small Molecules, MicroRNA, Electroporation, Viral Vectors) and By End Users (Pharmaceutical Companies, Research Institutes, Biotechnology Companies, Academic Institutions) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Induced Pluripotent Stem Cells Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Application (USD Million)
      1. 4.1.1 Regenerative Medicine
      2. 4.1.2 Drug Discovery
      3. 4.1.3 Disease Modeling
      4. 4.1.4 Toxicology Testing
      5. 4.1.5 Gene Therapy
    2. 4.2 Pharmaceutical, BY Cell Type (USD Million)
      1. 4.2.1 Cardiomyocytes
      2. 4.2.2 Neurons
      3. 4.2.3 Hepatocytes
      4. 4.2.4 Pancreatic Cells
      5. 4.2.5 Mesenchymal Stem Cells
    3. 4.3 Pharmaceutical, BY Source of Induction (USD Million)
      1. 4.3.1 Transcription Factors
      2. 4.3.2 Small Molecules
      3. 4.3.3 MicroRNA
      4. 4.3.4 Electroporation
      5. 4.3.5 Viral Vectors
    4. 4.4 Pharmaceutical, BY End User (USD Million)
      1. 4.4.1 Pharmaceutical Companies
      2. 4.4.2 Research Institutes
      3. 4.4.3 Biotechnology Companies
      4. 4.4.4 Academic Institutions
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Fujifilm Cellular Dynamics (JP)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Astellas Pharma Inc. (JP)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Takeda Pharmaceutical Company Limited (JP)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Roche Holding AG (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Lonza Group AG (CH)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Thermo Fisher Scientific Inc. (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Merck KGaA (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Celerion (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY APPLICATION
    3. 6.3 US MARKET ANALYSIS BY CELL TYPE
    4. 6.4 US MARKET ANALYSIS BY SOURCE OF INDUCTION
    5. 6.5 US MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY CELL TYPE, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY CELL TYPE, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY SOURCE OF INDUCTION, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY SOURCE OF INDUCTION, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY CELL TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY SOURCE OF INDUCTION, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Million, 2025-2035)

  • Regenerative Medicine
  • Drug Discovery
  • Disease Modeling
  • Toxicology Testing
  • Gene Therapy

Pharmaceutical By Cell Type (USD Million, 2025-2035)

  • Cardiomyocytes
  • Neurons
  • Hepatocytes
  • Pancreatic Cells
  • Mesenchymal Stem Cells

Pharmaceutical By Source of Induction (USD Million, 2025-2035)

  • Transcription Factors
  • Small Molecules
  • MicroRNA
  • Electroporation
  • Viral Vectors

Pharmaceutical By End User (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Research Institutes
  • Biotechnology Companies
  • Academic Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $ $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓